ES8603272A1 - Procedimiento de producir un preparado de farmaco de toxicidad reducida - Google Patents

Procedimiento de producir un preparado de farmaco de toxicidad reducida

Info

Publication number
ES8603272A1
ES8603272A1 ES532818A ES532818A ES8603272A1 ES 8603272 A1 ES8603272 A1 ES 8603272A1 ES 532818 A ES532818 A ES 532818A ES 532818 A ES532818 A ES 532818A ES 8603272 A1 ES8603272 A1 ES 8603272A1
Authority
ES
Spain
Prior art keywords
procedure
producing
reduced toxicity
drug preparation
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES532818A
Other languages
English (en)
Other versions
ES532818A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Publication of ES8603272A1 publication Critical patent/ES8603272A1/es
Publication of ES532818A0 publication Critical patent/ES532818A0/es
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROCEDIMIENTO PARA PREPARAR UN FARMACO DE TOXICIDAD REDUCIDA. CARACTERIZADO POR MEZCLAR PREVIAMENTE FARMACOS CUYOS EFECTOS SECUNDARIOS TOXICOS SON MEDIADOS A TRAVES DE SU FIJACION A RECEPTORES CELULARES ENDOGENOS DE NATURALEZA LIPIDICA, CON DETERMINADOS LIGANDOS LIPIDICOS QUE REDUCEN LA TOXICIDAD DEL FARMACO SIN ALTERAR SU ACTIVIDAD FARMACOLOGICA AL IMPEDIR LA FIJACION DEL MISMO A SU RECEPTOR DE TOXICIDAD.
ES532818A 1983-05-26 1984-05-25 Procedimiento de producir un preparado de farmaco de toxicidad reducida Granted ES532818A0 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49826883A 1983-05-26 1983-05-26
US60450384A 1984-05-02 1984-05-02

Publications (2)

Publication Number Publication Date
ES8603272A1 true ES8603272A1 (es) 1985-12-16
ES532818A0 ES532818A0 (es) 1985-12-16

Family

ID=27052776

Family Applications (1)

Application Number Title Priority Date Filing Date
ES532818A Granted ES532818A0 (es) 1983-05-26 1984-05-25 Procedimiento de producir un preparado de farmaco de toxicidad reducida

Country Status (7)

Country Link
US (1) US4897384A (es)
KR (1) KR850002401A (es)
CA (1) CA1237670A (es)
ES (1) ES532818A0 (es)
GR (1) GR79953B (es)
IL (1) IL71908A0 (es)
IT (1) IT1178947B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409704A (en) * 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US4871718A (en) * 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
US20010051183A1 (en) * 1989-10-20 2001-12-13 Alza Corporation Liposomes with enhanced circulation time and method of treatment
CA2120234A1 (en) * 1991-10-21 1993-04-29 Jack B. Jiang 2-aminopropan-1,3-diol chemotherapeutic agents
WO1994012155A1 (en) * 1992-12-02 1994-06-09 Vestar, Inc. Antibiotic formulation and process
US5958449A (en) * 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
JPH09502700A (ja) * 1993-04-02 1997-03-18 ザ リポソーム カンパニー、インコーポレーテッド リポソームの製造方法
US5759571A (en) * 1993-05-11 1998-06-02 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for drug resistant infections
ES2154680T3 (es) 1993-07-08 2001-04-16 Liposome Co Inc Metodo para controlar el tamaño de los liposomas.
US5716526A (en) * 1994-01-14 1998-02-10 The Liposome Company, Inc. Method of separating materials from liposomes or lipid complexes
US6045774A (en) * 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
AU740918B2 (en) * 1997-01-10 2001-11-15 Plantibodies Corporation Novel epithelial tissue targeting agent
US6165997A (en) * 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
US6258375B1 (en) * 1998-03-05 2001-07-10 Abbott Laboratories Antibacterial phosphoinositides
US6194379B1 (en) 1998-05-01 2001-02-27 Abbott Laboratories Elemental enteral formula
AU6502699A (en) * 1998-09-30 2000-04-17 University Of Utah Research Foundation Delivery of phosphoinositide polyphosphates into cells
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
AU2003230600B2 (en) * 2002-03-05 2009-06-04 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
AU2003304204B2 (en) * 2002-10-29 2009-12-24 Insmed Incorporated Sustained release of antiinfectives
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
ES2798263T3 (es) 2005-12-08 2020-12-10 Insmed Inc Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
PL2852391T3 (pl) 2012-05-21 2022-04-11 Insmed Incorporated Układy do leczenia infekcji płuc
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
MX384843B (es) 2014-05-15 2025-03-14 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
EP3787602A4 (en) 2018-05-02 2022-03-23 Insmed Incorporated PROCESS FOR THE MANUFACTURE OF LIPOSOMAL DRUG FORMULATIONS
EP4312536A1 (en) 2021-04-01 2024-02-07 Vestaron Corporation Liposome formulations for pesticide delivery and methods for producing and using the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962429A (en) * 1973-08-01 1976-06-08 Chugai Seiyaku Kabushiki Kaisha Method for reducing side effects of aminoglycoside antibiotics and composition therefor
TR19072A (tr) * 1973-11-26 1978-05-01 Pepro Fosforlu tuerevler ihtiva eden fungisid terkipler
US4119724A (en) * 1973-11-26 1978-10-10 Pepro Fungicidal compositions containing phosphorous acid and derivatives thereof
US3993754A (en) * 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4160827A (en) * 1978-02-06 1979-07-10 The Upjohn Company Metronidazole phosphate and salts
US4263428A (en) * 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IL55431A (en) * 1978-08-24 1982-07-30 Yeda Res & Dev Anthracycline type antibiotics,their preparation and pharmaceutical compositions comprising them
DE2856333C2 (de) * 1978-12-27 1983-09-22 A. Nattermann & Cie GmbH, 5000 Köln Oral einnehmbare Arzneimittel mit entzündungshemmender Wirkung
US4272525A (en) * 1978-10-23 1981-06-09 Schering Corporation Derivatives of polyene macrolide antibiotics containing an amino sugar moiety, process for the preparation thereof, and pharmaceutical compositions containing them
GR73668B (es) * 1978-11-21 1984-03-28 Hoffmann La Roche
GB2046092B (en) * 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4291027A (en) * 1979-03-07 1981-09-22 Engelhard Minerals & Chemicals Corp. Method for treating tumors with ethylenediamine platinum (II) and 1,2-diaminocyclohexane-platinum (II) pyrophosphate complexes
US4291023A (en) * 1979-03-07 1981-09-22 Engelhard Minerals & Chemicals Corp. Method for treating tumors using cis-diammineplatinum (II) organophosphate complexes
US4287187A (en) * 1979-03-07 1981-09-01 Engelhard Minerals & Chemicals Corporation Method for treating tumors with cis-diammineplatinum(II) orthophosphate complexes
JPS55127162A (en) * 1979-03-22 1980-10-01 Fujio Kurata System and apparatus for protecting insulator in electric dust collector
DE2914789A1 (de) * 1979-04-11 1980-10-16 Nattermann A & Cie Injizierbare arzneimittel mit entzuendungshemmender wirkung
CA1173360A (en) * 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
DE2952115C2 (de) * 1979-12-22 1982-05-06 A. Nattermann & Cie GmbH, 5000 Köln Rosmarinsäure-Phospholipid-Komplex
US4346084A (en) * 1980-02-29 1982-08-24 Massachusetts Institute Of Technology Process and composition for treating disorders by administering lithium and choline
US4430330A (en) * 1980-02-29 1984-02-07 Massachusetts Institute Of Technology Process and composition for treating disorders by administering a phenothiazine and choline
US4419348A (en) * 1981-04-27 1983-12-06 Georgetown University Anthracycline glycoside compositions, their use and preparation
US4397846A (en) * 1981-05-15 1983-08-09 Murray Weiner Storage-stable lipid vesicles and method of preparation
DE3125422A1 (de) * 1981-06-27 1983-01-27 A. Nattermann & Cie GmbH, 5000 Köln Neue fungizid-zusammensetzung, verfahren zur herstellung und deren verwendung
DE3125423A1 (de) * 1981-06-27 1983-01-13 A. Nattermann & Cie GmbH, 5000 Köln Neue insektizid-zusammensetzung, verfahren zur herstellung und deren verwendung

Also Published As

Publication number Publication date
US4897384A (en) 1990-01-30
IT1178947B (it) 1987-09-16
ES532818A0 (es) 1985-12-16
GR79953B (es) 1984-10-31
IT8467535A1 (it) 1985-11-25
IT8467535A0 (it) 1984-05-25
CA1237670A (en) 1988-06-07
IL71908A0 (en) 1984-09-30
KR850002401A (ko) 1985-05-13

Similar Documents

Publication Publication Date Title
ES8201596A1 (es) Procedimiento de obtencion de mucopolisacaridos
NO875299D0 (no) Insulinpreparat for ikke-paranteral administrasjon.
ATE5508T1 (de) Praeparate zur parenteralen verabreichung fettloeslicher wirkstoffe.
NL190664C (nl) Gesubstitueerde benzhydrylpiperidinoderivaten met therapeutische werking en farmaceutische preparaten die deze verbindingen bevatten.
AU4690379A (en) Administering intravenous drugs
SG18792G (en) Drug preparations of reduced toxicity
DE3580616D1 (de) Mitomycinderivate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
MX18786A (es) Complejos macrociclicos de acido aminofonico, su preparacion, formulaciones y empleo.
IT8723126A0 (it) Derivati dell'acido tiazolidin 4carbossilico ad attivita'farmaceutica.
DK160429C (da) N-heterocyclisk glycosid med antitumorvirkning, fremstilling deraf samt farmaceutisk praeparat indeholdende glycosidet
FR2361404A1 (fr) Nouvelles 7-boxyiminoacylcephalosporines, leurs procedes de preparation et leur application en therapeutique
IT8025159A0 (it) Preparato medicinale ad azione citostatica, nonche' derivati dell'acido isocianurico eprocedimento per la loro preparazione.
FI864164A7 (fi) Ihmis- -interferonin biologisesti aktiivisia johdoksia, niiden valmistus ja tällaisia johdoksia sisältävlääkkeitä.
DE3164719D1 (en) Drugs with cytostatic activity, derivatives of isocyanuric acid and process for their preparation
DE3867086D1 (de) Benzothiepino(5,4-c)pyridazin-verbindungen und ihre pharmazeutischen wirkungen.
NL192520B (nl) Gesubstitueerde tetrahydrofuranderivaten met anti-PAF-werking, werkwijze voor hun bereiding en farmaceutische preparaten die hen bevat.
ZA772514B (en) Improvements relating to the administration of pharmaceutically active substances to animals
IE781117L (en) Medicament comprising erythromycin and metoclopramide
AU585279B2 (en) Pesticidal biphenylyloxy and biphenylylalkoxy aryl acyl urea compounds
FI74003B (fi) Foerfarande foer framstaellning av en terapeutiskt anvaendbar 5,14-dihydrobens/5,6/isoindolo/2,1-b/isokinolin- 8,13-dion.
IT8722218A0 (it) Ftalazino derivati ad attivita'farmaceutica.
RU1779254C (ru) Способ получени производных индоло /2,3-в/-хиноксалина
NO167982C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive penemderivater.
GB1477996A (en) Quinolizine derivatives and their preparation
SE8802997L (sv) Aminderivat och dess salt, foerfarande foer framstaellning daerav och medel mot saar innehaallande desamma